Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.

@article{Ascierto2013PhaseIT,
  title={Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.},
  author={Paolo Antonio Ascierto and David Minor and Antoni Ribas and C{\'e}l{\`e}ste Lebb{\'e} and Anne O'Hagan and Niki Arya and Mary E Guckert and Dirk Schadendorf and Richard F. Kefford and Jean Jacques Grob and Omid A. Hamid and Ravi K Amaravadi and Ester Simeone and Tabea Wilhelm and Kevin B Kim and Georgina V Long and A M Martin and Jolly Mazumdar and Vicki L Goodman and Uwe Trefzer},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2013},
  volume={31 26},
  pages={3205-11}
}
PURPOSE Dabrafenib (GSK2118436) is a potent inhibitor of mutated BRAF kinase. Our multicenter, single-arm, phase II study assessed the safety and clinical activity of dabrafenib in BRAF(V600E/K) mutation-positive metastatic melanoma (mut(+) MM). PATIENTS AND METHODS Histologically confirmed patients with stage IV BRAF(V600E/K) mut(+) MM received oral dabrafenib 150 mg twice daily until disease progression, death, or unacceptable adverse events (AEs). The primary end point was investigator… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 8 times over the past 90 days. VIEW TWEETS